Clinical Trial Update: the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial) [Phase 3]

View source ↗

Summary

Phase 3 REFSAL trial update on an inhaled β2-adrenergic receptor agonist for Transient Tachypnea of the Newborn; the study is currently active and not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Pulmonary Hypertension of the Newborn
• Respiratory Failure
• Transient Tachypnea of the Newborn

Drugs mentioned

• Inhaled β2-adrenergic receptor agonist (unspecified)

Snippet

Sponsor: Medical University of Warsaw | Conditions: TTN, Respiratory Failure | Phase 3 | Status: ACTIVE_NOT_RECRUITING